<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0"
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main" xml:id="_xJh4Thz">Risk-Based Treatment for Patients With First Relapse or Progression of Rhabdomyosarcoma: A Report From the Children&apos;s Oncology Group</title>
				<funder ref="#_39Xy5bh #_b7TAuP8">
					<orgName type="full">National Cancer Institute</orgName>
					<orgName type="abbreviated">NCI</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/100000054</idno>
				</funder>
				<funder ref="#_SAfjMjj #_YN7Cxfq">
					<orgName type="full">unknown</orgName>
				</funder>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability  status="unknown">
					<licence/>
					<p type="raw">Â© 2019 American Cancer Society. /cncr.32122, Wiley Online Library on [16/07/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License</p>
				</availability>
				<date type="published" when="2019-08-01">August 1, 2019</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><roleName>MD, MS</roleName><forename type="first">Leo</forename><surname>Mascarenhas</surname></persName>
							<email>lmascarenhas@chla.usc.edu</email>
							<idno type="ORCID">0000-0001-7790-0777</idno>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Saban Research Institute , Children&apos;s Hospital Los Angeles , 4650 Sunset Boulevard , Mail Stop 54 , Los Angeles , CA 90027 ;</note>
								<orgName type="institution" key="instit1">Saban Research Institute</orgName>
								<orgName type="institution" key="instit2">Children&apos;s Hospital Los Angeles</orgName>
								<address>
									<addrLine>4650 Sunset Boulevard Mail Stop 54</addrLine>
									<postCode>90027</postCode>
									<settlement>Los Angeles</settlement>
									<region>CA</region>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>2</label> Saban Research Institute , Children&apos;s Hospital Los Angeles , Los Angeles , California; Division of Hematology, Oncology, and Blood and Marrow Transplantation ,</note>
								<orgName type="department">Division of Hematology, Oncology,</orgName>
								<orgName type="laboratory">Blood and Marrow Transplantation</orgName>
								<orgName type="institution" key="instit1">Saban Research Institute</orgName>
								<orgName type="institution" key="instit2">Children&apos;s Hospital Los Angeles</orgName>
								<address>
									<settlement>Los Angeles</settlement>
									<region>California;</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MS</roleName><forename type="first">Elizabeth</forename><forename type="middle">R</forename><surname>Lyden</surname></persName>
							<affiliation key="aff2">
								<note type="raw_affiliation"><label>3</label> Department of Pediatrics , Keck School of Medicine , University of Southern California , Los Angeles , California;</note>
								<orgName type="department" key="dep1">Department of Pediatrics</orgName>
								<orgName type="department" key="dep2">Keck School of Medicine</orgName>
								<orgName type="institution">University of Southern California</orgName>
								<address>
									<settlement>Los Angeles</settlement>
									<region>California;</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Philip</forename><forename type="middle">P</forename><surname>Breitfeld</surname></persName>
							<affiliation key="aff3">
								<note type="raw_affiliation"><label>4</label> Department of Preventive and Societal Medicine , University of Nebraska , Omaha , Nebraska ;</note>
								<orgName type="department">Department of Preventive and Societal Medicine</orgName>
								<orgName type="institution">University of Nebraska</orgName>
								<address>
									<settlement>Omaha</settlement>
									<region>Nebraska</region>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<note type="raw_affiliation"><label>5</label> Duke University Medical Center , Durham , North Carolina;</note>
								<orgName type="institution">Duke University Medical Center</orgName>
								<address>
									<settlement>Durham</settlement>
									<region>North Carolina;</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">David</forename><forename type="middle">O</forename><surname>Walterhouse</surname></persName>
							<affiliation key="aff6">
								<note type="raw_affiliation"><label>6</label> Department of Pediatrics , Ann &amp; Robert H. Lurie Children&apos;s Hospital of Chicago , Northwestern University Feinberg School of Medicine , Chicago , Illinois ;</note>
								<orgName type="department" key="dep1">Department of Pediatrics</orgName>
								<orgName type="department" key="dep2">Ann &amp; Robert H</orgName>
								<orgName type="institution" key="instit1">Lurie Children&apos;s Hospital of Chicago</orgName>
								<orgName type="institution" key="instit2">Northwestern University Feinberg School of Medicine</orgName>
								<address>
									<settlement>Chicago</settlement>
									<region>Illinois</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Sarah</forename><forename type="middle">S</forename><surname>Donaldson</surname></persName>
							<affiliation key="aff7">
								<note type="raw_affiliation"><label>7</label> Department of Radiation Oncology , Stanford University , Stanford , California;</note>
								<orgName type="department">Department of Radiation Oncology</orgName>
								<orgName type="institution">Stanford University</orgName>
								<address>
									<settlement>Stanford</settlement>
									<region>California;</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">David</forename><forename type="middle">A</forename><surname>Rodeberg</surname></persName>
							<affiliation key="aff8">
								<note type="raw_affiliation"><label>8</label> Division of Pediatric Surgery , Department of Surgery , East Carolina University , Greenville , North Carolina;</note>
								<orgName type="department" key="dep1">Division of Pediatric Surgery</orgName>
								<orgName type="department" key="dep2">Department of Surgery</orgName>
								<orgName type="institution">East Carolina University</orgName>
								<address>
									<settlement>Greenville</settlement>
									<region>North Carolina;</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">David</forename><forename type="middle">M</forename><surname>Parham</surname></persName>
							<affiliation key="aff9">
								<note type="raw_affiliation"><label>9</label> Department of Pathology , Children&apos;s Hospital Los Angeles , Keck School of Medicine , University of Southern California , Los Angeles , California;</note>
								<orgName type="department" key="dep1">Department of Pathology</orgName>
								<orgName type="department" key="dep2">Keck School of Medicine</orgName>
								<orgName type="institution" key="instit1">Children&apos;s Hospital Los Angeles</orgName>
								<orgName type="institution" key="instit2">University of Southern California</orgName>
								<address>
									<settlement>Los Angeles</settlement>
									<region>California;</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Ja</forename><forename type="middle">R</forename><surname>Anderson</surname></persName>
							<idno type="ORCID">0000-0003-3602-1375</idno>
							<affiliation key="aff2">
								<note type="raw_affiliation"><label>3</label> Department of Pediatrics , Keck School of Medicine , University of Southern California , Los Angeles , California;</note>
								<orgName type="department" key="dep1">Department of Pediatrics</orgName>
								<orgName type="department" key="dep2">Keck School of Medicine</orgName>
								<orgName type="institution">University of Southern California</orgName>
								<address>
									<settlement>Los Angeles</settlement>
									<region>California;</region>
								</address>
							</affiliation>
							<affiliation key="aff10">
								<note type="raw_affiliation"><label>10</label> Oncology , Merck Research Laboratories , North Wales , Pennsylvania ;</note>
								<orgName type="laboratory">Oncology</orgName>
								<orgName type="institution">Merck Research Laboratories</orgName>
								<address>
									<settlement>North Wales</settlement>
									<region>Pennsylvania</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">William</forename><forename type="middle">H</forename><surname>Meyer</surname></persName>
							<affiliation key="aff11">
								<note type="raw_affiliation"><label>11</label> Department of Pediatrics , University of Oklahoma Health Sciences Center , Oklahoma City , Oklahoma ;</note>
								<orgName type="department">Department of Pediatrics</orgName>
								<orgName type="institution">University of Oklahoma Health Sciences Center</orgName>
								<address>
									<settlement>Oklahoma City</settlement>
									<region>Oklahoma</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Douglas</forename><forename type="middle">S</forename><surname>Hawkins</surname></persName>
							<idno type="ORCID">0000-0003-3602-1375</idno>
							<affiliation key="aff12">
								<note type="raw_affiliation"><label>12</label> Department of Pediatrics , Seattle Children&apos;s Hospital , Fred Hutchinson Cancer Research Center , University of Washington , Seattle , Washington.</note>
								<orgName type="department" key="dep1">Department of Pediatrics</orgName>
								<orgName type="department" key="dep2">Fred Hutchinson Cancer Research Center</orgName>
								<orgName type="institution" key="instit1">Seattle Children&apos;s Hospital</orgName>
								<orgName type="institution" key="instit2">University of Washington</orgName>
								<address>
									<settlement>Seattle</settlement>
									<region>Washington</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff5">
								<note type="raw_affiliation">Breitfeld Group, LLC , Chapel Hill , North Carolina;</note>
								<orgName type="institution">Breitfeld Group, LLC</orgName>
								<address>
									<settlement>Chapel Hill</settlement>
									<region>North Carolina;</region>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main" xml:id="_jjhadP7">Risk-Based Treatment for Patients With First Relapse or Progression of Rhabdomyosarcoma: A Report From the Children&apos;s Oncology Group</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2019-08-01">August 1, 2019</date>
						</imprint>
					</monogr>
					<idno type="MD5">04CE89B0507356EEE9424CB26091E144</idno>
					<idno type="DOI">10.1002/cncr.32122</idno>
					<note type="submission">Received: December 15, 2018; Revised: March 13, 2019; Accepted: March 14, 2019,</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.2" ident="GROBID" when="2025-08-31T10:29+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<label type="revision">a91ee48</label>
					<label type="parameters">startPage=-1, endPage=-1, consolidateCitations=2, consolidateHeader=2, consolidateFunders=1, includeRawAffiliations=true, includeRawCitations=true, includeRawCopyrights=true, generateTeiIds=true, generateTeiCoordinates=[all], sentenceSegmentation=true, flavor=null</label>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term xml:id="_CBQF8Fp">recurrent</term>
					<term xml:id="_CUuxQMY">refractory</term>
					<term xml:id="_GREevbt">relapse</term>
					<term xml:id="_zYqac7Y">rhabdomyosarcoma</term>
					<term xml:id="_y5qzjEJ">treatment</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_4Z4NNK6">BACKGROUND:</head><p xml:id="_3uMEY37"><s xml:id="_bvFgaVV">The purpose of this study was to evaluate risk and response-based multi-agent therapy for patients with rhabdomyosarcoma (RMS) at first relapse.</s><s xml:id="_CDTSHwS">METHODS: Patients with RMS and measurable disease at first relapse with unfavorable-risk (UR) features were randomized to a 6-week phase 2 window with 1 of 2 treatment schedules of irinotecan with vincristine (VI) (previously reported).</s><s xml:id="_5UQUqyz">Those with at least a partial response to VI continued to receive 44 weeks of multi-agent chemotherapy including the assigned VI regimen.</s><s xml:id="_jMYpgJH">UR patients who did not have measurable disease at study entry, did not have a radiographic response after the VI window, or declined VI window therapy received 31 weeks of multi-agent chemotherapy including tirapazamine (TPZ) at weeks 1, 4, 10, 19, and 28.</s><s xml:id="_qdGuk6A">Favorable-risk (FR) patients received 31 weeks of the same multi-agent chemotherapy without VI and TPZ.</s><s xml:id="_Z6EEJJ9">RESULTS: One hundred thirty-six eligible patients were enrolled.</s><s xml:id="_Phxyyx6">For 61 patients not responding to VI, the 3-year failure-free survival (FFS) and overall survival (OS) rates were 17% (95% confidence interval [CI], 8%-29%) and 24% (13%-37%), respectively.</s><s xml:id="_4PDJSMk">For 30 UR patients not treated with VI, the 3-year FFS and OS rates were 21% (8%-37%) and 39% (20%-57%), respectively.</s><s xml:id="_HA2Sgev">FR patients had 3-year FFS and OS rates of 79% (47%-93%) and 84% (50%-96%), respectively.</s><s xml:id="_JTSwVXZ">There were no unexpected toxicities.</s><s xml:id="_dew73uN">CONCLUSIONS: Patients with UR RMS at first relapse or disease progression have a poor prognosis when they are treated with this multi-agent therapy, whereas FR patients have a higher chance of being cured with second-line therapy.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<facsimile>
		<surface n="1" ulx="0.0" uly="0.0" lrx="584.787" lry="782.929"/>
		<surface n="2" ulx="0.0" uly="0.0" lrx="584.787" lry="782.929"/>
		<surface n="3" ulx="0.0" uly="0.0" lrx="584.787" lry="782.929"/>
		<surface n="4" ulx="0.0" uly="0.0" lrx="584.787" lry="782.929"/>
		<surface n="5" ulx="0.0" uly="0.0" lrx="584.787" lry="782.929"/>
		<surface n="6" ulx="0.0" uly="0.0" lrx="584.787" lry="782.929"/>
		<surface n="7" ulx="0.0" uly="0.0" lrx="584.787" lry="782.929"/>
		<surface n="8" ulx="0.0" uly="0.0" lrx="584.787" lry="782.929"/>
	</facsimile>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_mneCsBg">INTRODUCTION</head><p xml:id="_fcVpGsr"><s xml:id="_AKyzrsb">Rhabdomyosarcoma (RMS) is the most common soft-tissue sarcoma of childhood and adolescence. <ref type="bibr" target="#b0">1</ref></s><s xml:id="_egYgfdu">Multimodality therapy with surgery, radiation therapy, and cytotoxic chemotherapy has resulted in approximately 70% of patients achieving long-term survival. <ref type="bibr" target="#b1">2</ref></s><s xml:id="_wHYrmmP">However, patients who are refractory to primary therapy and those who relapse after primary therapy have a poor prognosis. <ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref></s><s xml:id="_vXz72qd">4]<ref type="bibr" target="#b4">[5]</ref> This is true especially for patients with stage 2 to 4, clinical group II to IV embryonal rhabdomyosarcoma (ERMS); those with stage 1 or clinical group I ERMS who were initially treated with vincristine, dactinomycin, and cyclophosphamide (VAC); and those with alveolar RMS. <ref type="bibr" target="#b2">3</ref> In aggregate, these unfavorable-risk (UR) patients have a 5-year postrelapse survival rate of approximately 10%.</s><s xml:id="_mwPUgep">In contrast, a more favorable-risk (FR) group is composed of those with botryoid histology or stage 1 or clinical group I ERMS treated at diagnosis with vincristine and dactinomycin, for whom the survival rate is approximately 50%. <ref type="bibr" target="#b2">3</ref> The Soft Tissue Sarcoma Committee of the Children's Oncology Group (COG) chose to evaluate the activity of 2 schedules of irinotecan together with vincristine (VI) in a 6-week phase 2 window in those patients with UR and measurable disease at the time of first relapse followed by multi-agent therapy incorporating VI for patients who achieved Cancer August 1, 2019 at least a partial response (PR) at 6 weeks.</s><s xml:id="_4fFTN34">We have previously reported the rationale, early response rates for the 2 VI schedules, and outcomes for UR patients treated with the VI window. <ref type="bibr" target="#b5">6</ref></s><s xml:id="_zVjYszq">The study enrolled 2 additional categories of patients.</s><s xml:id="_zhkKSEa">The first category included UR patients without measurable disease at study entry, those who declined VI phase 2 window therapy, and those who did not achieve a radiographic response after 6 weeks of VI therapy.</s><s xml:id="_867jH7D">These patients received the same multiagent therapy without VI but with the addition of tirapazamine (TPZ), a hypoxic cell toxin.</s><s xml:id="_mGD79gf">The second category included FR patients who received multi-agent therapy without VI or TPZ.</s><s xml:id="_3d6dthD">Here, we report toxicities and outcomes for these 2 categories of patients.</s></p><p xml:id="_8wu5sgj"><s xml:id="_TDNfhnz">TPZ, a benzotriazine di-N-oxide anticancer drug that is activated to a toxic free radical under hypoxic conditions, was the first drug of this class to enter clinical testing. <ref type="bibr" target="#b6">7</ref></s><s xml:id="_a6hdDBp">In preclinical models, additive or greater than additive cytotoxicity was noted when TPZ was combined with cytotoxic chemotherapy, presumably by selective killing of hypoxic tumor cells. <ref type="bibr" target="#b7">8,</ref><ref type="bibr" target="#b8">9</ref></s><s xml:id="_rT2aYwS">A phase 1 clinical trial in adults defined the maximum tolerated dose of TPZ as 330 mg/m 2 when administered intravenously once every 3 weeks as a single agent. <ref type="bibr" target="#b9">10</ref></s><s xml:id="_AwAk99u">Reversible deafness and tinnitus were dose-limiting toxicities in this trial.</s><s xml:id="_u2W7mwe">In adult studies, TPZ was safely administered together with cytotoxic chemotherapy, <ref type="bibr" target="#b10">11</ref> although patients experienced significantly more nausea and vomiting. <ref type="bibr" target="#b11">12</ref></s><s xml:id="_dVHEGuR">There were no differences in hematopoietic toxicity when TPZ was investigated in a randomized phase 3 clinical trial with cisplatin in adult patients with non-small cell lung cancer. <ref type="bibr" target="#b10">11</ref></s><s xml:id="_kYfX7VS">A pediatric phase 1 trial of the TPZ and cyclophosphamide combination demonstrated a maximum tolerated dose of 325 mg/m 2 for TPZ when it was combined with 1.5 g/m 2 of cyclophosphamide intravenously. <ref type="bibr" target="#b12">13</ref></s><s xml:id="_XTGcmsf">The dose-limiting toxicity was reversible ototoxicity.</s><s xml:id="_NrkX7RA">There were 3 responses, including 1 in a patient with RMS.</s></p><p xml:id="_Zb7VTAs"><s xml:id="_BXqdxB7">The majority of newly diagnosed patients with RMS in North America are treated with VAC chemotherapy.</s><s xml:id="_my2r5bh">Phase 2 clinical trials with doxorubicin, ifosfamide, and etoposide for RMS <ref type="bibr" target="#b13">14</ref> formed the basis for the risk-based multi-agent treatment regimens for patients with RMS with first relapse or disease progression investigated in this clinical trial.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_ZS8RAgR">MATERIALS AND METHODS</head><p xml:id="_SQVeEcv"><s xml:id="_YXVQ349">Patients eligible for COG ARST0121 had biopsyproven RMS, undifferentiated sarcoma or ectomesenchymoma, and were younger than 21 years at the time of the initial diagnosis; had experienced first relapse or disease progression; and had an Eastern Cooperative Oncology Group performance status of 0, 1, or 2 and a life expectancy of at least 2 months.</s><s xml:id="_hqBvKBK">Adequate organ function was required; this included a hemoglobin level â¥10 g/dL (transfusion allowed), an absolute neutrophil count â¥750/mm 3 , a platelet count â¥75,000/mm 3 , a serum creatinine level â¤1.5 times the normal for age or a creatinine clearance/radioisotope glomerular filtration rate â¥70 mL/min/1.73</s><s xml:id="_r2KfSP9">m 2 , a serum bilirubin level â¤1.5 times the normal for age, a serum alanine transaminase level â¤2.5 times the normal for age, and a left ventricular shortening fraction â¥27% by echocardiogram or an ejection fraction â¥50% by gated radionuclide scan.</s><s xml:id="_GBgCDKV">Any prior central nervous system toxicity had to be less than grade 2, and adequate control of any seizure disorder with anticonvulsants was required.</s><s xml:id="_XuzWpsE">Patients who had received more than 1 prior chemotherapy treatment regimen, those with prior exposure to anthracyclines, ischemic heart disease, myeloablative chemotherapy followed by hematopoietic stem cell rescue, or disease impinging on or within the brain and spinal cord, and those who were pregnant/lactating were excluded.</s><s xml:id="_MC9tKDj">Written informed consent was required from all subjects and/or their parents/legal guardians after institutional, Food and Drug Administration, and National Cancer Institute (NCI) requirements for human studies were met.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_rSuvu5H">Clinical Trial Design</head><p xml:id="_5MUTRgd"><s xml:id="_ktZFsqj">The experimental design of the ARST0121 trial is shown in Figure <ref type="figure" target="#fig_0">1</ref>.</s><s xml:id="_ceEwNRH">Consenting patients with UR features (stage 2-4, clinical group II-IV ERMS at the initial diagnosis; stage I or clinical group I ERMS at the initial diagnosis with distant recurrence after vincristine and dactinomycin or recurrence after VAC; and alveolar RMS at the initial diagnosis), with measurable disease (defined as 1 or more lesions with a diameter â¥10 mm) at study entry, and with no prior exposure to irinotecan were randomized to 1 of 2 VI treatment schedules followed by multi-agent chemotherapy that incorporated the assigned VI schedule for responding patients (regimens 1A and 1B; Table <ref type="table" target="#tab_0">1</ref>).</s><s xml:id="_SgdAzH6">Patients who did not respond to the VI phase 2 window were switched to multi-agent chemotherapy without VI but with TPZ at week 7 (regimen 2; Table <ref type="table" target="#tab_0">1</ref>).</s><s xml:id="_rAzeaNZ">Patients with UR features at the time of first relapse or disease progression without measurable disease at study entry, those who had previous exposure to irinotecan, and those who declined randomization to the VI phase 2 window also received multi-agent Cancer August 1, 2019 chemotherapy without VI but with TPZ (regimen 2).</s><s xml:id="_GSMhDXN">TPZ was supplied by the NCI (IND #46525).</s><s xml:id="_vKZqtPa">Patients with FR features (botryoid histology at the initial diagnosis or stage 1 or clinical group I ERMS at the initial diagnosis not treated with cyclophosphamide, and who recurred locally or regionally) at the time of first relapse or disease progression received multi-agent chemotherapy without VI or TPZ starting at week 1 (regimen 3;  Table 1).</s><s xml:id="_cQ8sM7Y">Disease response was assessed with the NCI's Response Evaluation Criteria in Solid Tumors 15 at week 6 for patients on regimens 1 and 2. Patients on regimen 1 who did not respond to the VI phase 2 window at week 6 had a second disease response assessment at week 12 after 2 cycles of TPZ administered together with doxorubicin and cyclophosphamide.</s></p><p xml:id="_TNuuRSc"><s xml:id="_7JA4jhj">Surgical resection of disease at previously irradiated sites was strongly encouraged if feasible.</s><s xml:id="_6SnGSUh">Radiation therapy was administered (50.4 Gy for macroscopic disease and 41.4 Gy for microscopic disease) at sites of disease that were not previously irradiated at the discretion of the treating physician either during weeks 16 to 22 in regimen 1A and 1B or during weeks 10 to 18 in regimens 2 and 3. Intraoperative radiation therapy or brachytherapy was recommended after surgical resection for patients with disease at sites that were previously irradiated.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_zjCFn8D">Statistical Analyses</head><p xml:id="_bWxEj7F"><s xml:id="_QDGqQS3">Analyses comparing the response rates, toxicities, failurefree survival (FFS), and overall survival (OS) of patients treated on regimens 1A and 1B have been previously reported. <ref type="bibr" target="#b5">6</ref></s><s xml:id="_tcKWBjd">The primary endpoint for patients on regimen 2 was toxicity.</s><s xml:id="_7G8brhZ">Toxicities were reported with the NCI's Common Terminology Criteria (version 2.0).</s><s xml:id="_GT9nW8Y">On the basis of known toxicities of TPZ, there was monitoring for ototoxicity, cardiotoxicity, stomatitis, hematopoietic toxicity, and grade 3 vomiting with stopping rules.</s><s xml:id="_g2mnpSs">A dose-limiting toxicity was defined as a grade 4 infection, a â¥40-db hearing loss at 2000 MHz lasting more than 5 days, grade 3 or higher vomiting, grade 3 or higher cardiac toxicity, or grade 3 or higher 3 stomatitis.</s><s xml:id="_wzwFbQX">An ototoxicity rate of 15%, a grade 3 or higher cardiac toxicity rate of 10%, a grade 3 or higher stomatitis rate of 35%, and an incidence of grade 4 infection or grade 3 vomiting of 25% were set as the acceptable upper bounds for these toxicities, above which enrollment would be suspended and modification of the treatment protocol would be considered.</s><s xml:id="_9V58V86">The response rate and the OS were the secondary endpoints for patients treated with regimen 2. A complete response (CR) was defined as the disappearance of all target lesions by cross-sectional computed tomography or magnetic resonance imaging, a partial response (PR) was defined as a â¥30% decrease in the dimension used to define the target lesion, progressive disease (PD) was defined as a â¥20% increase in the measurement used to define the target lesion, and stable disease was defined as a decrease or increase in the tumor insufficient to be considered a PR or PD.</s><s xml:id="_xWT4dRV">The estimations of FFS and OS were performed with the Kaplan-Meier method.</s><s xml:id="_bDNf5Kg">FFS was defined as the time of enrollment to disease progression or death. <ref type="bibr" target="#b15">16</ref></s><s xml:id="_etUmqvk">Confidence intervals (CIs) for FFS and OS were estimated by the Peto-Peto method. <ref type="bibr" target="#b16">17</ref></s><s xml:id="_AggGEdb">OS was defined as the time from enrollment to death from any cause.</s><s xml:id="_CYVdnpF">The primary endpoint for regimen 3 was FFS.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_JWFZCHh">RESULTS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_Vh8ByBT">Patient Characteristics</head><p xml:id="_ZxzKdsM"><s xml:id="_SMrK2sE">COG ARST0121 enrolled 139 patients between June 2002 and October 2006 (Fig. <ref type="figure" target="#fig_0">1</ref>), and 3 were deemed ineligible (enrollment error [n = 1], a lack of informed consent [n = 1], and the initiation of therapy before enrollment [n = 1]).</s><s xml:id="_rBJkv9J">Fourteen patients with FR features were treated on regimen 3, and the remaining 122 patients were either randomized to 1 of the 2 VI schedules (n = 92) or assigned to regimen 2 (n = 30 [including 2 patients with measurable disease who declined randomization to the VI phase 2 window]).</s><s xml:id="_etfx38G">The characteristics of those patients treated on regimens 1A and 1B have been previously reported. <ref type="bibr" target="#b5">6</ref></s><s xml:id="_yQ2SBYF">The characteristics of patients treated on regimen 2 or 3 are shown in Table <ref type="table" target="#tab_2">2</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_QuKT4v6">Toxicity</head><p xml:id="_j3WTYTd"><s xml:id="_FY2GY6h">Toxicity was evaluated for the first 6 weeks of therapy on regimens 1A and 1B and has been reported previously. <ref type="bibr" target="#b5">6</ref></s><s xml:id="_TuydsUD">inety-one patients were treated with regimen 2 (including patients not responding to the VI phase 2 window) The numbers indicate the distribution of sites of recurrence.</s><s xml:id="_HpUJK2M">Patients may have had more than 1 site of recurrence.</s></p><p xml:id="_9scQYDa"><s xml:id="_VBsXFsQ">Cancer August 1, 2019</s></p><p xml:id="_QJXE9Rs"><s xml:id="_yJDXPRg">and received TPZ combined with doxorubicin and cyclophosphamide.</s><s xml:id="_wnNP9V2">Grade 3 or higher toxicities experienced during the first 6 weeks (2 cycles) included vomiting (26.8%), stomatitis (12%), myalgia (8.5%), infection (5%), heart failure (6%), and ototoxicity (2.4%).</s><s xml:id="_EMxE3gy">There was 1 death due to congestive heart failure that occurred immediately after the first dose of TPZ administered to a patient who was refractory to regimen 1A.</s><s xml:id="_ahx3H7D">All other toxicities were expected from the known toxicity profile of TPZ and were less than the a priori determined boundaries requiring TPZ dose de-escalation or protocol therapy modifications.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_zv4fXnZ">Tumor Response</head><p xml:id="_5c6M7WF"><s xml:id="_r4ByNbj">Response rates at week 6 in 89 evaluable patients after treatment on regimens 1A and 1B have been previously reported and were 26% and 36%, respectively (combined response rate, 31.5%). <ref type="bibr" target="#b5">6</ref></s><s xml:id="_t2HqP5C">Twenty-four of the 30 patients assigned to regimen 2 were evaluable for a response.</s><s xml:id="_Zpbj5xu">There were 6 CRs and 7 PRs after 6 weeks of therapy with TPZ, doxorubicin, and cyclophosphamide for an overall objective response rate (CRs + PRs) of 54%.</s><s xml:id="_8JgfXch">Sixty-one patients who did not respond to the VI phase 2 window were treated with regimen 2. Forty-nine of these patients were evaluable for a response, and they had a response rate of 22% after 6 weeks of TPZ, doxorubicin, and cyclophosphamide.</s><s xml:id="_D74wdWP">No patient in this group achieved a CR.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_SkrxmpC">Survival Outcomes</head><p xml:id="_rfxxCPZ"><s xml:id="_fAc2u92">The 3-year FFS rates for all patients are summarized in Table <ref type="table" target="#tab_3">3</ref> by regimen.</s><s xml:id="_6ubDzME">The overall outcomes for patients treated with the VI window have been reported previously. <ref type="bibr" target="#b5">6</ref></s><s xml:id="_STKdE9h">Patients randomized to regimen 1A had 3-year FFS and OS rates of 14% (95% CI, 5%-27%) and 34% (95% CI, 20%-49%), respectively, whereas those randomized to regimen 1B had a 3-year FFS rate of 15% (95% CI, 7%-26%) and an OS rate of 22% (95% CI, 11%-35%).</s><s xml:id="_S9Z5h8p">Patients ineligible for the VI phase 2 window had 3-year FFS and OS rates of 21% (95% CI, 8%-37%) and 39% (95% CI, 20%-57%), respectively, after treatment on regimen 2 (Fig. <ref type="figure" target="#fig_1">2</ref>).</s><s xml:id="_UnfAVay">The 3-year FFS and OS rates for patients who did not respond to VI were 17% (95% CI, 8%-29%) and 24% (95% CI, 13%-37%), respectively.</s><s xml:id="_peQjBV8">Figure <ref type="figure" target="#fig_2">3</ref> displays 3-year FFS and OS rates for the 14 FR patients treated on regimen 3. The 3-year FFS and OS rates for FR patients were 79% (95% CI, 47%-93%) and 84% (95% CI, 50%-96%), respectively.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_EESpCMY">DISCUSSION</head><p xml:id="_BteFqHr"><s xml:id="_MfgZxzh">There is no defined standard therapy for patients with relapsed or progressive RMS.</s><s xml:id="_axntagR">In general, these patients are treated with intensive multi-agent chemotherapy with or without surgery and/or radiation therapy.</s><s xml:id="_bcTjkVH">Other therapeutic options include enrollment in phase 1 or 2 clinical trials with new agents.</s><s xml:id="_SWSmbJd">Before ARST0121, no clinical trial had prospectively investigated protocol-defined multi-agent chemotherapy exclusively for patients with RMS at first relapse or disease progression.</s><s xml:id="_rGTSzdy">In addition to comparing prolonged and shorter VI schedules in a phase 2 window, ARST0121 investigated risk-based therapy for patients with first-relapse RMS on the basis of previously defined UR or FR features.</s><s xml:id="_RGWzqsf">ARST0121 represents the largest clinical trial conducted for relapsed/refractory RMS.</s><s xml:id="_HMFKfUb">This clinical trial confirms the poor outcomes for patients with firstrelapse RMS and UR features.</s><s xml:id="_sXShbTx">In addition, it confirms the favorable outcomes among the minority of patients with lower stage/clinical group disease and ERMS or botryoid RMS when they are treated with multi-agent therapy.</s></p><p xml:id="_Ucf2xp2"><s xml:id="_3cRBvF8">The toxicity in this trial was as expected and was similar to that of other regimens used for the treatment of pediatric solid tumors at diagnosis or after relapse. <ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref></s><s xml:id="_9cdSZUc">9]<ref type="bibr" target="#b19">[20]</ref> The response rate of 31.5% for VI was modest, <ref type="bibr" target="#b5">6</ref> particularly in comparison with the 70% response rate seen in an upfront phase 2 window trial of previously untreated patients with metastatic RMS. <ref type="bibr" target="#b20">21</ref></s><s xml:id="_s2DhMMv">fter the investigation of the VI phase 2 window in the first-relapse setting for RMS, the combination was investigated with alternating cycles of VAC chemotherapy in newly diagnosed patients with intermediate-risk RMS by COG (ARST0531), but it failed to improve outcomes. <ref type="bibr" target="#b21">22</ref></s><s xml:id="_DbzGUMU">The objective response rate in this trial for TPZ, doxorubicin, and cyclophosphamide ranged from 22% to 54%.</s><s xml:id="_FxuFxRz">The lower response rate of 22% in the group of patients who did not respond to VI suggests that those patients had inherently more resistant disease at the time of first relapse in comparison with those treated with regimen 2 immediately at the   Cancer August 1, 2019 not support further investigation of TPZ in RMS and is consistent with the results of 2 phase 3 trials in adults with carcinomas, in which TPZ failed to improve outcomes. <ref type="bibr" target="#b22">23,</ref><ref type="bibr" target="#b23">24</ref></s><s xml:id="_2KdbVzc">Patients treated on regimen 2 at initial relapse cannot be compared with patients treated on regimen 2 after no response to the VI window because the latter group is presumed to be inherently more resistant and thus a different population.</s></p><p xml:id="_Rpjr4j4"><s xml:id="_mWK5uSV">Local control with radiation therapy and surgery can be challenging in the management of patients with relapsed RMS, particularly if there is local tumor progression at previously irradiated sites.</s><s xml:id="_2QshTsA">These data were not collected in ARST0121; therefore, its impact on outcomes could not be analyzed.</s></p><p xml:id="_wuT6a8s"><s xml:id="_AcPrjht">Patients with botryoid RMS with first relapse and those with either stage 1 or clinical group I ERMS with local/regional recurrence who were not treated with cyclophosphamide at the original diagnosis had favorable outcomes when they were treated with multi-agent therapy.</s><s xml:id="_hYwwbSg">Such patients should, therefore, generally not be considered candidates for investigational therapy in single-agent phase 2 or 1 clinical trials at the time of first relapse.</s><s xml:id="_zVG5YsR">COG's recent low-risk RMS trial ARST0331 showed excellent outcomes with shorter duration (22-week) therapy with a modest cumulative cyclophosphamide dose (4.8 g/m 2 ), and this suggests that all low-risk patients with RMS might receive some cyclophosphamide in the future to allow shorter therapy. <ref type="bibr" target="#b24">25</ref></s><s xml:id="_qpyzvJN">It is unknown whether the same excellent outcomes seen with regimen 3 in patients without prior cyclophosphamide exposure will be seen in patients who relapse after modest cyclophosphamide treatment but otherwise have FR features.</s></p><p xml:id="_GUQ4f4Z"><s xml:id="_Hh9GhQT">Importantly, this clinical trial showed prospectively a median FFS rate of 50% at 6 months in patients with RMS with UR features at first relapse/ progression.</s><s xml:id="_9xreDrH">This establishes a survival benchmark that can be used in future investigations in patients with RMS with UR features at first relapse or progression.</s><s xml:id="_hYhtMQt">Given our increased understanding of the molecular basis of cancer and the availability of targeted therapy, COG investigated the combination of molecularly targeted therapy and a cytotoxic chemotherapy backbone in a randomized phase 2 clinical trial in the UR group of patients with RMS at the time of first relapse or disease progression.</s><s xml:id="_xxjNPrt">The mammalian target of rapamycin inhibitor temsirolimus improved progression-free survival in comparison with the vascular endothelial growth factor inhibitor bevacizumab (L.</s><s xml:id="_uQk2bXb">Mascarenhas, ASCO 2014). <ref type="bibr" target="#b25">26</ref></s><s xml:id="_Yy8eU2g">To improve survival for patients with RMS, novel strategies are required either to improve the outcomes for patients with recurrent disease or to decrease the relapse rate in newly diagnosed patients.</s><s xml:id="_XdSZuQ7">Optimizing treatment to improve FFS for newly diagnosed patients with RMS is thus of paramount importance because of the poor survival outcomes following relapse and the increased burden of therapy to cure those who survive.</s><s xml:id="_AcEGCj7">Genomic studies may provide further insight to inform further investigations into relapsed RMS, and other strategies such as immune check point blockade and epigenetic modification provide more avenues to explore. <ref type="bibr" target="#b26">27,</ref><ref type="bibr" target="#b27">28</ref></s><s xml:id="_zKvm3U6">This clinical trial prospectively confirms risk features for RMS at the time of first relapse/progression and provides a unique model for clinical investigation in patients with relapsed RMS.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 .</head><label>1</label><figDesc><div><p xml:id="_dDTpNyw"><s xml:id="_R2AdDzb">Figure 1.</s><s xml:id="_C7y8UJ4">Consolidated Standards of Reporting Trials diagram for COG ARST0121.</s><s xml:id="_HUk9dgb">COG indicates Children's Oncology Group; PR, partial response; RMS, rhabdomyosarcoma.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2 .</head><label>2</label><figDesc><div><p xml:id="_7TsXGKZ"><s xml:id="_MyBrjQh">Figure 2. Probability of FFS and OS for patients with unfavorable features not responding to vincristine and irinotecan.</s><s xml:id="_TqewR6K">FFS indicates failure-free survival; OS, overall survival.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 3 .</head><label>3</label><figDesc><div><p xml:id="_VadqaeE"><s xml:id="_tejHCnD">Figure 3. Probability of FFS and OS for patients with favorable features treated on regimen 3. FFS indicates failure-free survival; OS, overall survival.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>TABLE 1 .</head><label>1</label><figDesc><div><p xml:id="_wnKtCCh"><s xml:id="_VD6eu69">Treatment Regimens for Patients</s></p></div></figDesc><table><row><cell>Chemotherapy</cell><cell>Regimen 1A</cell><cell>Regimen 1B</cell><cell>Regimen 2</cell><cell>Regimen 3</cell></row><row><cell>Irinotecan (IV)</cell><cell>20 mg/m 2 Ã 5 d</cell><cell>50 mg/m 2 Ã 5 d</cell><cell>None</cell><cell>None</cell></row><row><cell></cell><cell>Weeks 1, 2, 4, 5, 13, 14, 25, 26, 34, 35, 46,</cell><cell>Weeks 1, 4, 13, 25, 34,</cell><cell></cell><cell></cell></row><row><cell></cell><cell>47, 49, and 50</cell><cell>46, and 49</cell><cell></cell><cell></cell></row><row><cell>Vincristine (IV; 1.5 mg/m 2 ) a</cell><cell>Weeks 1, 2, 4, 5, 13, 14, 25, 26, 34, 35, 46,</cell><cell>Identical to 1A</cell><cell>None</cell><cell>None</cell></row><row><cell></cell><cell>47, 49, and 50</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Doxorubicin (IV; 75 mg/m 2 )</cell><cell>Weeks 7, 16, 28, 37, and 40</cell><cell>Identical to 1A</cell><cell cols="2">Weeks 1, 4, 10, 19, and 28 Identical to 2</cell></row><row><cell cols="2">Cyclophosphamide (IV; 1.2 g/m 2 ) Weeks 7, 16, 28, 37, and 40</cell><cell>Identical to 1A</cell><cell cols="2">Weeks 1, 4, 10, 19, and 28 Identical to 2</cell></row><row><cell>Etoposide (IV; 100 mg/m 2 /d Ã 5)</cell><cell>Weeks 10, 19, 22, 31, and 43</cell><cell>Identical to 1A</cell><cell>Weeks 7, 13, 16, 22, 25,</cell><cell>Identical to 2</cell></row><row><cell></cell><cell></cell><cell></cell><cell>and 31</cell><cell></cell></row><row><cell>Ifosfamide (IV; 1.8 g/m 2 /d Ã 5)</cell><cell>Weeks 10, 19, 22, 31, and 43</cell><cell>Identical to 1A</cell><cell>Weeks 7, 13, 16, 22, 25,</cell><cell>Identical to 2</cell></row><row><cell></cell><cell></cell><cell></cell><cell>and 31</cell><cell></cell></row><row><cell>Tirapazamine (IV; 330 mg/m 2 )</cell><cell>None</cell><cell>None</cell><cell cols="2">Weeks 1, 4, 10, 19, and 28 None</cell></row><row><cell>Abbreviation: IV, intravenous.</cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note xml:id="_JEMK2fU"><p>a</p><p>The maximum dose was 2 mg.</p><p><s xml:id="_Nh6WY96">Cancer August 1, 2019</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>TABLE 2 .</head><label>2</label><figDesc><div><p xml:id="_VwSNQhV"><s xml:id="_TgjauHS">Patient Characteristics</s></p></div></figDesc><table><row><cell></cell><cell>Regimen 2</cell><cell>Regimen 3</cell></row><row><cell>Patient Characteristic</cell><cell>(n = 30)</cell><cell>(n = 14)</cell></row><row><cell>Age</cell><cell></cell><cell></cell></row><row><cell>&lt;10 y</cell><cell>14</cell><cell>8</cell></row><row><cell>â¥10 y</cell><cell>16</cell><cell>6</cell></row><row><cell>Sex</cell><cell></cell><cell></cell></row><row><cell>Male</cell><cell>20</cell><cell>6</cell></row><row><cell>Female</cell><cell>10</cell><cell>8</cell></row><row><cell>Histology</cell><cell></cell><cell></cell></row><row><cell>Alveolar</cell><cell>19</cell><cell>0</cell></row><row><cell>Embryonal</cell><cell>6</cell><cell>10</cell></row><row><cell>Other</cell><cell>5</cell><cell>4</cell></row><row><cell>Primary site (at original diagnosis) a</cell><cell></cell><cell></cell></row><row><cell>Favorable</cell><cell>1</cell><cell>14</cell></row><row><cell>Unfavorable</cell><cell>29</cell><cell>0</cell></row><row><cell>Recurrence b</cell><cell></cell><cell></cell></row><row><cell>Local</cell><cell>10</cell><cell>9</cell></row><row><cell>Regional lymph nodes</cell><cell>7</cell><cell>5</cell></row><row><cell>Bone marrow/bone</cell><cell>7</cell><cell>0</cell></row><row><cell>Other distant sites</cell><cell>18</cell><cell>0</cell></row><row><cell>Regimen 1 was previously reported.</cell><cell></cell><cell></cell></row></table><note xml:id="_Ww3DVRG"><p><s xml:id="_MGfexDD">a Favorable sites included the following: orbit, nonparameningeal head and neck, nonbladder/prostate genitourinary, and biliary.</s><s xml:id="_3yvfbE2">Unfavorable sites included all others.</s><s xml:id="_CprzuAQ">b</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>TABLE 3 .</head><label>3</label><figDesc><div><p xml:id="_8s8kT2h"><s xml:id="_yE4CyZD">Three-Year Postrelapse/Progression Outcomes According to the Regimen</s></p></div></figDesc><table><row><cell></cell><cell>Failure-Free Survival,</cell><cell>Overall Survival, %</cell></row><row><cell>Regimen</cell><cell>% (95% CI)</cell><cell>(95% CI)</cell></row><row><cell>1A</cell><cell>14 (5-27)</cell><cell>34 (20-49)</cell></row><row><cell>1B</cell><cell>15 (7-26)</cell><cell>22 (11-35)</cell></row><row><cell>2 a</cell><cell>17 (8-29)</cell><cell>24 (13-37)</cell></row><row><cell>2 b</cell><cell>21 (8-37)</cell><cell>39 (20-57)</cell></row><row><cell>3</cell><cell>79 (47-93)</cell><cell>84 (50-96)</cell></row><row><cell cols="2">Abbreviation: CI, confidence interval.</cell><cell></cell></row><row><cell cols="3">a Unfavorable-risk patients with no radiographic response on the phase 2</cell></row><row><cell>window.</cell><cell></cell><cell></cell></row><row><cell cols="3">b Unfavorable-risk patients ineligible for the phase 2 window.</cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_0"><p xml:id="_XM94dTv"><s xml:id="_SjkcNx8">10970142, 2019, 15, Downloaded from https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.32122,</s><s xml:id="_jtDfcBQ">Wiley Online Library on [16/07/2025].</s><s xml:id="_cFKhkJy">See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions)</s><s xml:id="_DP8a8p6">on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License</s></p></note>
		</body>
		<back>

			<div type="funding">
<div><head xml:id="_y2D6Wmd">FUNDING SUPPORT</head><p xml:id="_rMGcvTV"><s xml:id="_WrxjVsk">This study was supported by the <rs type="funder">National Cancer Institute</rs> (grants <rs type="grantNumber">U10CA180886</rs>, <rs type="grantNumber">U10CA180899</rs>, <rs type="grantNumber">U10CA98543</rs>, and <rs type="grantNumber">U10CA98413</rs>).</s></p></div>
			</div>
			<listOrg type="funding">
				<org type="funding" xml:id="_39Xy5bh">
					<idno type="grant-number">U10CA180886</idno>
				</org>
				<org type="funding" xml:id="_b7TAuP8">
					<idno type="grant-number">U10CA180899</idno>
				</org>
				<org type="funding" xml:id="_SAfjMjj">
					<idno type="grant-number">U10CA98543</idno>
				</org>
				<org type="funding" xml:id="_YN7Cxfq">
					<idno type="grant-number">U10CA98413</idno>
				</org>
			</listOrg>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_UWnqMMM">CONFLICT OF INTEREST DISCLOSURES</head><p xml:id="_bWu6jsW"><s xml:id="_k3TbPdu">Leo Mascarenhas reports grants to his institution from AstraZeneca Pharmaceuticals LP; grants, nonfinancial support, and other to his institution from Eli Lilly and Company; personal fees for service in a speakers' bureau (from October 1, 2018 to February 22, 2019) from Bayer Pharma AG; and grants to his institution from Novartis Pharmaceuticals Corporation, Merck Sharpe and Dome Corporation, and E.R. Squibb and Sons LLC for work performed outside the current study.</s><s xml:id="_jTGDmcv">Philip P. Breitfeld is employed by and owns stock in Quintiles, owns stock in and is a board member for Champions Oncology, and has received personal fees from Grid Therapeutics for work performed outside the current study.</s><s xml:id="_vYmspmH">David A. Rodeberg reports travel, accommodation, and expenses from Navidea.</s><s xml:id="_r5969Ng">James R. Anderson has received grants from the National Cancer Institute's Cancer Therapy Evaluation Program for work performed as part of the current study; he also reports being employed by and owning stock in Merck and acting as a consultant for Merck, Amgen, and SFS Pharma.</s><s xml:id="_WGVKyuC">Douglas S. Hawkins reports that he was reimbursed for travel, lodging, and food to attend medical advisory board meetings for Loxo Oncology, Bristol-Myers Squibb, Celgene, and Bayer and that his institution received funds to cover the cost of conducting a clinical trial from Loxo Oncology, Lilly, Eisai, Merck Sharpe and Dome Corporation, Novartis, GlaxoSmithKline, and Sanofi.</s><s xml:id="_rmAwTG4">The other authors made no disclosures.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_jXW2cVD">AUTHOR CONTRIBUTIONS</head><p xml:id="_63VTqWq"><s xml:id="_RfXFv35">Leo Mascarenhas: Collection and assembly of data, data analysis and interpretation, manuscript writing, and final approval of manuscript.</s><s xml:id="_8Dr6EuR">Elizabeth R. Lyden: Data analysis and interpretation, manuscript writing, and final approval of manuscript.</s><s xml:id="_GEQz7JR">Philip P. Breitfeld: Conception and design, collection and assembly of data, manuscript writing, and final approval of manuscript.</s><s xml:id="_86Hneg3">David O. Walterhouse: Conception and design, collection and assembly of data, data analysis and interpretation, manuscript writing, and final approval of manuscript.</s><s xml:id="_zGjVR6c">Sarah S. Donaldson: Data analysis and interpretation, manuscript writing, and final approval of manuscript.</s><s xml:id="_DXywhkC">David A. Rodeberg: Conception and design, collection and assembly of data, data analysis and interpretation, manuscript writing, and final approval of manuscript.</s><s xml:id="_3nrdJUV">David M. Parham: Collection and assembly of data, data analysis and interpretation, manuscript writing, and final approval of manuscript.</s><s xml:id="_9XREdeK">James R. Anderson: Conception and design, collection and assembly of data, data analysis and interpretation, manuscript writing, and final approval of manuscript.</s><s xml:id="_jw8eGQ4">William H.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_UYwzCQZ">Cancer August 1, 2019</head><p xml:id="_gYwG5MU"><s xml:id="_YCwNXYq">Meyer: Conception and design, data analysis and interpretation, manuscript writing, final approval of manuscript, and administrative support.</s><s xml:id="_3GE6Yew">Douglas S. Hawkins: Conception and design, collection and assembly of data, data analysis and interpretation, manuscript writing, and final approval of manuscript.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main" xml:id="_k5WrKRT">Cancer incidence among children and adolescents in the United States, 2001-2003</title>
		<author>
			<persName><forename type="first">J</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">D</forename><surname>Thompson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Pollack</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Stewart</surname></persName>
		</author>
		<idno type="DOI">10.1542/peds.2007-2964</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_KpKvwCY">Pediatrics</title>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="page" from="1470" to="1477" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Li J, Thompson TD, Miller JW, Pollack LA, Stewart SL. Cancer in- cidence among children and adolescents in the United States, 2001- 2003. Pediatrics. 2008;121:e1470-1477.</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main" xml:id="_Z5wEruS">Rhabdomyosarcoma: review of the Children&apos;s Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies</title>
		<author>
			<persName><forename type="first">S</forename><surname>Malempati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Hawkins</surname></persName>
		</author>
		<idno type="DOI">10.1002/pbc.24118</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_PcMcVGm">Pediatr Blood Cancer</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="5" to="10" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Malempati S, Hawkins DS. Rhabdomyosarcoma: review of the Children&apos;s Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies. Pediatr Blood Cancer. 2012;59:5-10.</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main" xml:id="_kgttrPj">Survival after relapse in children and adolescents with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Pappo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Anderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">M</forename><surname>Crist</surname></persName>
		</author>
		<idno type="DOI">10.1200/jco.1999.17.11.3487</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_GarNUgA">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="3487" to="3493" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Pappo AS, Anderson JR, Crist WM, et al. Survival after relapse in children and adolescents with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group. J Clin Oncol. 1999;17:3487-3493.</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main" xml:id="_yzeDyfy">Prognosis of children with soft tissue sarcoma who relapse after achieving a complete response. A report from the Intergroup Rhabdomyosarcoma Study I</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Raney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">M</forename><surname>Crist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Maurer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Foulkes</surname></persName>
		</author>
		<idno type="DOI">10.1002/1097-0142(19830701)52:1&lt;44::aid-cncr2820520110&gt;3.0.co;2-v</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ZUJRh4P">Cancer</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="44" to="50" />
			<date type="published" when="1983">1983</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Raney RB, Crist WM, Maurer HM, Foulkes MA. Prognosis of chil- dren with soft tissue sarcoma who relapse after achieving a complete response. A report from the Intergroup Rhabdomyosarcoma Study I. Cancer. 1983;52:44-50.</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main" xml:id="_dJRG2KX">Prognostic factors after relapse in nonmetastatic rhabdomyosarcoma: a nomogram to better define patients who can be salvaged with further therapy</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Chisholm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Marandet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rey</surname></persName>
		</author>
		<idno type="DOI">10.1200/jco.2010.32.1984</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_qQWNh3g">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="1319" to="1325" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Chisholm JC, Marandet J, Rey A, et al. Prognostic factors after re- lapse in nonmetastatic rhabdomyosarcoma: a nomogram to better de- fine patients who can be salvaged with further therapy. J Clin Oncol. 2011;29:1319-1325.</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main" xml:id="_7v6N5es">Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children&apos;s Oncology Group</title>
		<author>
			<persName><forename type="first">L</forename><surname>Mascarenhas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">R</forename><surname>Lyden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">P</forename><surname>Breitfeld</surname></persName>
		</author>
		<idno type="DOI">10.1200/jco.2010.29.7390</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_unz9zy5">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="4658" to="4663" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Mascarenhas L, Lyden ER, Breitfeld PP, et al. Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children&apos;s Oncology Group. J Clin Oncol. 2010; 28:4658-4663.</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main" xml:id="_cvF78c4">The unique physiology of solid tumors: opportunities (and problems) for cancer therapy</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Giaccia</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_VuqSDgt">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="1408" to="1416" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Brown JM, Giaccia AJ. The unique physiology of solid tumors: op- portunities (and problems) for cancer therapy. Cancer Res. 1998; 58:1408-1416.</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main" xml:id="_s52pD24">Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Dorie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Brown</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_n78QvqU">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page" from="4633" to="4636" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Dorie MJ, Brown JM. Tumor-specific, schedule-dependent inter- action between tirapazamine (SR 4233) and cisplatin. Cancer Res. 1993;53:4633-4636.</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main" xml:id="_MjTMdjD">Synergistic interaction between tirapazamine and cyclophosphamide in human breast cancer xenografts</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">K</forename><surname>Langmuir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Rooker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Osen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">L</forename><surname>Mendonca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">R</forename><surname>Laderoute</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_tYtCHpH">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="2845" to="2847" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Langmuir VK, Rooker JA, Osen M, Mendonca HL, Laderoute KR. Synergistic interaction between tirapazamine and cyclo- phosphamide in human breast cancer xenografts. Cancer Res. 1994;54:2845-2847.</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main" xml:id="_9kNF3BM">Phase I and pharmacokinetic study of tirapazamine (SR 4233) administered every three weeks</title>
		<author>
			<persName><forename type="first">S</forename><surname>Senan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Rampling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Graham</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0959-8049(02)80747-x</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_UH8Vaxj">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="31" to="38" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Senan S, Rampling R, Graham MA, et al. Phase I and pharmaco- kinetic study of tirapazamine (SR 4233) administered every three weeks. Clin Cancer Res. 1997;3:31-38.</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main" xml:id="_RPTSmK6">Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors</title>
		<author>
			<persName><forename type="first">J</forename><surname>Von Pawel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Von</forename><surname>Roemeling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gatzemeier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename></persName>
		</author>
		<idno type="DOI">10.1200/jco.2000.18.6.1351</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_CuQSj7k">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="1351" to="1359" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
	<note type="raw_reference">von Pawel J, von Roemeling R, Gatzemeier U, et al. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors. J Clin Oncol. 2000; 18:1351-1359.</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main" xml:id="_Y9JVUM4">Phase I study of tirapazamine and cisplatin in patients with recurrent cervical cancer</title>
		<author>
			<persName><forename type="first">C</forename><surname>Aghajanian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O'</forename><surname>Flaherty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename></persName>
		</author>
		<idno type="DOI">10.1006/gyno.1997.4841</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_4nFyk8F">Gynecol Oncol</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="127" to="130" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Aghajanian C, Brown C, O&apos;Flaherty C, et al. Phase I study of ti- rapazamine and cisplatin in patients with recurrent cervical cancer. Gynecol Oncol. 1997;67:127-130.</note>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main" xml:id="_2zyyKev">Phase I trial of tirapazamine and cyclophosphamide in children with refractory solid tumors: a Pediatric Oncology Group study</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">M</forename><surname>Aquino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Weitman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Winick</surname></persName>
		</author>
		<idno type="DOI">10.1200/jco.2004.07.111</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_6vTtDjd">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="1413" to="1419" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Aquino VM, Weitman SD, Winick NJ, et al. Phase I trial of tirapa- zamine and cyclophosphamide in children with refractory solid tumors: a Pediatric Oncology Group study. J Clin Oncol. 2004; 22:1413-1419.</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main" xml:id="_VrYQdMm">Soft Tissue Sarcoma Committee of the Children&apos;s Oncology Group. Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children&apos;s Oncology Group</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Lager</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">R</forename><surname>Lyden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Anderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Pappo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Meyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">P</forename><surname>Breitfeld</surname></persName>
		</author>
		<idno type="DOI">10.1200/jco.2005.01.9497</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_t7CZFHk">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="3415" to="3422" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lager JJ, Lyden ER, Anderson JR, Pappo AS, Meyer WH, Breitfeld PP; Soft Tissue Sarcoma Committee of the Children&apos;s Oncology Group. Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children&apos;s Oncology Group. J Clin Oncol. 2006;24:3415-3422.</note>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main" xml:id="_xZNkjKS">New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada</title>
		<author>
			<persName><forename type="first">P</forename><surname>Therasse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Arbuck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Eisenhauer</surname></persName>
		</author>
		<idno type="DOI">10.1093/jnci/92.3.205</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_cxUQpgA">J Natl Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">92</biblScope>
			<biblScope unit="page" from="205" to="216" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evalu- ate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main" xml:id="_PPR2BzN">Nonparametric estimation from incomplete observations</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">L</forename><surname>Kaplan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Meier</surname></persName>
		</author>
		<idno type="DOI">10.1080/01621459.1958.10501452</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_dadNX6E">J Am Stat Assoc</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page" from="457" to="481" />
			<date type="published" when="1958">1958</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main" xml:id="_daH4GrJ">Asymptotically efficient rank invariant test procedures</title>
		<author>
			<persName><forename type="first">R</forename><surname>Peto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Peto</surname></persName>
		</author>
		<idno type="DOI">10.2307/2344317</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_AveVCJ5">J R Stat Soc Ser A</title>
		<imprint>
			<biblScope unit="volume">135</biblScope>
			<biblScope unit="page" from="185" to="198" />
			<date type="published" when="1972">1972</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Peto R, Peto J. Asymptotically efficient rank invariant test proce- dures. J R Stat Soc Ser A. 1972;135:185-198.</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main" xml:id="_tgy3JRD">Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children&apos;s Oncology Group Study</title>
		<author>
			<persName><forename type="first">L</forename><surname>Granowetter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Womer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Devidas</surname></persName>
		</author>
		<idno type="DOI">10.1200/jco.2008.19.1478</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_XqsCcyy">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="2536" to="2541" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Granowetter L, Womer R, Devidas M, et al. Dose-intensified com- pared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children&apos;s Oncology Group Study. J Clin Oncol. 2009;27:2536-2541.</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main" xml:id="_FUJ8hew">Very intensive, short-term chemotherapy for children and adolescents with metastatic sarcomas</title>
		<author>
			<persName><forename type="first">J</forename><surname>Felgenhauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hawkins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Pendergrass</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Lindsley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">U</forename><surname>Conrad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Miser</surname></persName>
		</author>
		<idno type="DOI">10.1002/(sici)1096-911x(200001)34:1&lt;29::aid-mpo6&gt;3.0.co;2-7</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_EpNMTxj">Med Pediatr Oncol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="29" to="38" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Felgenhauer J, Hawkins D, Pendergrass T, Lindsley K, Conrad EU, Miser JS. Very intensive, short-term chemotherapy for chil- dren and adolescents with metastatic sarcomas. Med Pediatr Oncol. 2000;34:29-38.</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main" xml:id="_D9gNX9X">Outcome of pediatric recurrent and refractory malignant solid tumors following ifosfamide/carboplatin/etoposide (ICE): a phase II study in a pediatric oncology centre in Brazil</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Loss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ppa</forename><surname>Santos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">D</forename><surname>Leone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Brunetto</surname></persName>
		</author>
		<idno type="DOI">10.1002/pbc.10375</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_xhHrNt2">Pediatr Blood Cancer</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="139" to="144" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Loss JF, Santos PPA, Leone LD, Brunetto AL. Outcome of pediat- ric recurrent and refractory malignant solid tumors following ifos- famide/carboplatin/etoposide (ICE): a phase II study in a pediatric oncology centre in Brazil. Pediatr Blood Cancer. 2004;42:139-144.</note>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main" xml:id="_B6UdWDa">Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children&apos;s Oncology Group</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Pappo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Lyden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Breitfeld</surname></persName>
		</author>
		<idno type="DOI">10.1200/jco.2006.07.1720</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_yqKpUBF">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="362" to="369" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Pappo AS, Lyden E, Breitfeld P, et al. Two consecutive phase II win- dow trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children&apos;s Oncology Group. J Clin Oncol. 2007;25:362-369.</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main" xml:id="_yhmaVwX">Addition of vincristine and irinotecan to vincristine, dactinomycin, and cyclophosphamide does not improve outcome for intermediate-risk rhabdomyosarcoma: a report from the Children&apos;s Oncology Group</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Hawkins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">Y</forename><surname>Chi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Anderson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_FwXnqM6">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="2770" to="2777" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hawkins DS, Chi YY, Anderson JR, et al. Addition of vincristine and irinotecan to vincristine, dactinomycin, and cyclophosphamide does not improve outcome for intermediate-risk rhabdomyosar- coma: a report from the Children&apos;s Oncology Group. J Clin Oncol. 2018;36:2770-2777.</note>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main" xml:id="_vFmTdkt">Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group study</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Disilvestro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ali</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Craighead</surname></persName>
		</author>
		<idno type="DOI">10.1200/jco.2013.51.4265</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ungtCqZ">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="458" to="464" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">DiSilvestro PA, Ali S, Craighead PS, et al. Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carci- noma limited to the pelvis: a Gynecologic Oncology Group study. J Clin Oncol. 2014;32:458-464.</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main" xml:id="_jQf7cHh">Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group</title>
		<author>
			<persName><forename type="first">D</forename><surname>Rischin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Peters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O'</forename><surname>Sullivan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename></persName>
		</author>
		<idno type="DOI">10.1200/jco.2009.27.4449</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_bAH65NV">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="2989" to="2995" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Rischin D, Peters LJ, O&apos;Sullivan B, et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol. 2010;28:2989-2995.</note>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main" xml:id="_BKCSma7">Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children&apos;s Oncology Group</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">O</forename><surname>Walterhouse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Pappo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Meza</surname></persName>
		</author>
		<idno type="DOI">10.1200/jco.2014.55.6787</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_U4vN24d">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="3547" to="3552" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Walterhouse DO, Pappo AS, Meza JL, et al. Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children&apos;s Oncology Group. J Clin Oncol. 2014;32:3547-3552.</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main" xml:id="_gaXPNyv">Randomized phase II trial of bevacizumab and temsirolimus in combination with vinorelbine (V) and cyclophosphamide (C) for first relapse/disease progression of rhabdomyosarcoma (RMS): A report from the Children&apos;s Oncology Group (COG)</title>
		<author>
			<persName><forename type="first">L</forename><surname>Mascarenhas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Meyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">R</forename><surname>Lyden</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_94J3XtY">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page">5</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>suppl abstr 10003</note>
	<note type="raw_reference">Mascarenhas L, Meyer WH, Lyden ER, et al. Randomized phase II trial of bevacizumab and temsirolimus in combination with vinorel- bine (V) and cyclophosphamide (C) for first relapse/disease progression of rhabdomyosarcoma (RMS): A report from the Children&apos;s Oncology Group (COG). J Clin Oncol. 2014;32(suppl; abstr 10003) 5s.</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main" xml:id="_fBNv7eW">Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Shern</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Chmielecki</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_VURzxHX">Cancer Discov</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="216" to="231" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Shern JF, Chen L, Chmielecki J, et al. Comprehensive genomic anal- ysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov. 2014;4:216-231.</note>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main" xml:id="_qryxX7G">Disruption of CXCR27-mediated MDSC tumor trafficking enhances anti-PD1 efficacy</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Highfill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Cui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Giles</surname></persName>
		</author>
		<idno type="DOI">10.1126/scitranslmed.3007974</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Agz2tFN">Sci Transl Med</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="237" to="267" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Highfill SL, Cui Y, Giles AJ, et al. Disruption of CXCR27-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci Transl Med. 2014;6:237ra267.</note>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main" xml:id="_pHgpWV5">Integrated genetic and epigenetic analysis defines novel molecular subgroups in rhabdomyosarcoma</title>
		<author>
			<persName><forename type="first">M</forename><surname>Seki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Nishimura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Yoshida</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_8J7EsZ4">Nat Commun</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">7557</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Seki M, Nishimura R, Yoshida K, et al. Integrated genetic and epi- genetic analysis defines novel molecular subgroups in rhabdomyosar- coma. Nat Commun. 2015;6:7557.</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
